A 6-month Study to Evaluate Sulforaphane Effects in PD Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT05084365|
Recruitment Status : Not yet recruiting
First Posted : October 19, 2021
Last Update Posted : October 19, 2021
|Condition or disease||Intervention/treatment||Phase|
|Parkinson Disease||Drug: Sulforaphane Drug: Placebo||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||A 6-month Study to Evaluate Sulforaphane Effects in Treatment of Cognition Impairment of PD Patients|
|Estimated Study Start Date :||October 10, 2021|
|Estimated Primary Completion Date :||October 1, 2022|
|Estimated Study Completion Date :||December 31, 2022|
The goal of the study is to investigate whether adding sulforaphane will benefit cognitive function in individuals who have PD.
Sulforaphane is a compound that can be extracted from broccoli, Brussel sprouts, cabbage, and other cruciferous plants.
Placebo Comparator: placebo
The purpose of including placebo is to judge if the outcome is related to the study medication rather than other reasons.
- Cognitive improvement assessed using the MATRICS Consensus Cognitive Battery (MCCB) composite score [ Time Frame: 24 weeks ]The investigators will use the MATRICS Consensus Cognitive Battery (MCCB) Composite score as primary cognitive outcome measure
- Change of clinical symptoms by UPDRS [ Time Frame: 24 weeks ]The change of UPDRS at different follow up point
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05084365
|Contact: Renrong Wufirstname.lastname@example.org|
|Contact: Hainan Zhangemail@example.com|